Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer (Q79808747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

title

Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

1 reference

Yoshitaka Nishio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Yoshiaki Yamada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Hiroto Kokubo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Kogenta Nakamura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Shigeyuki Aoki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Tomohiro Taki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Nobuaki Honda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Atsuko Nakagawa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Shinsuke Saga

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

Kazuo Hara

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

27 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

110-115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

Estimates of cancer incidence and mortality in Europe in 1995

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

7 January 2021

Cancer statistics, 1989.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Best Practice No 176: Updated recommendations for HER2 testing in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Histologic grading of prostate cancer: a perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Immunohistochemical study of chromogranin A in Stage D2 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2006.01.060

10.1016/J.UROLOGY.2006.01.060

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16806433 AND SRC:MED&resulttype=core&format=json

26 December 2019

1 reference